Durvalumab ± tremelimumab + platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden.
Luis G Paz-AresMarina-Chiara GarassinoYuanbin ChenNiels ReinmuthKatsuyuki HottaArtem PoltoratskiyDmytro TrukhinMaximilian Johannes HochmairMustafa ÖzgüroğluJun Ho JiGalina StatsenkoNikolay Vladimirov ConevIgor BondarenkoLibor HavelGyörgy LosonczyMingchao XieZhongwu LaiNadia Godin-HeymannHelen MannHaiyi JiangYashaswi ShresthaJonathan Wade GoldmanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
OS benefit with first-line durvalumab plus EP in patients with ES-SCLC was observed regardless of PD-L1 or tTMB status. PD-L1 expression may prove to be a useful biomarker for combined treatment with PD-(L)1 and CTLA-4 inhibition, although this requires confirmation with an independent dataset.